Hannah N. Imlay
Rating: 5.0 of 5
( out of 11 reviews )

Hannah N. Imlay, MD, MS

Languages spoken: English

  • Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 11 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    August 29, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr Imlay is knowledgeable, thoughtful, and kind.

    March 14, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    She's an excellent doctor in every way. I appreciate her.

    February 08, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Kind,competent, caring, engaged,

    December 20, 2024
    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Excellent! Took her time and answered all my questions!

    February 01, 2024
    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Hannah is so amazing and so knowledgeable. She is very patient are very sweet and nice.

    December 01, 2023
    UH HOSPITALS AND CLINICS
    Rating: 5 out of 5

    Dr. Imlay is so knowledgeable and caring.

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Graduate Training Epidemiology - University of Washington School of Public Health M.Sc.
    Fellowship Infectious Diseases - University of Washington Fellow
    Residency Internal Medicine - University of Michigan Medical School Resident
    Internship Internal Medicine - University of Michigan Medical School Intern
    Professional Medical Medicine - Northwestern University Feinberg School of Medicine M.D.
    Undergraduate Chemistry & Molecular/Cellular Biology - University of Illinois at Urbana–Champaign B.S.

    Selected Publications

    Journal Article

    1. Payne J, Sutton JD, Blackburn BE, Bansod S, Imlay H, Spivak ES, Pupaibool J, Gililland JM, Certain LK (2025). Effect of oral antibiotics after two-stage revision for periprosthetic joint infection on subsequent antibiotic resistance within a national cohort of United States veterans. J Bone Jt Infect, 10(1), 7-14. (Read full publication)
    2. Imlay H, Ciarkowski CE, Bryson-Cahn C, Chan JD, Hartlage WP, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Kassamali Escobar Z, Vaughn VM (2024). Validation and generalizability of an asymptomatic bacteriuria metric in critical access hospitals. Infect Control Hosp Epidemiol, 46(2), 1-6. (Read full publication)
    3. Ciarkowski CE, Imlay HN, Bryson-Cahn C, Chan JD, Hartlage W, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Vaughn VM, Kassamali Escobar Z (2024). Antimicrobial stewardship to reduce overtreatment of asymptomatic bacteriuria in critical access hospitals: measuring a quality improvement intervention. Infect Control Hosp Epidemiol, 46(2), 1-7. (Read full publication)
    4. Imlay H, Greenlee SB, Tritle BJ, Fino NF, Spivak ES (2024). In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program. Antimicrob Steward Healthc Epidemiol, 4(1), e173. (Read full publication)
    5. Yamauchi J, Raghavan D, Imlay H, Jweehan D, Oygen S, Marineci S, Remport A, Hall IE, Molnar MZ (2024). Deceased Organ Donor HTLV Screening Practices Postelimination of Universal Screening in the United States. Transplant Direct, 10(10), e1707. (Read full publication)
    6. Imlay H, Gnann JW Jr, Rooney J, Peddi VR, Wiseman AC, Josephson MA, Kew C, Young JH, Adey DB, Samaniego-Picota M, Whitley RJ, Limaye AP (2024). A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy. Transpl Infect Dis, e14367. (Read full publication)
    7. Imlay H, Thorpe A, Vaughn VM (2024). When antimicrobial stewardship begins with microbiological test requests: the case of asymptomatic bacteriuria. Curr Opin Infect Dis, 37(6), 565-572. (Read full publication)
    8. Hosseini-Moghaddam SM, Kothari S, Humar A, Albasata H, Yetmar ZA, Razonable RR, Neofytos D, DAsaro M, Boggian K, Hirzel C, Khanna N, Manuel O, Mueller NJ, Imlay H, Kabbani D, Tyagi V, Smibert OC, Nasra M, Fontana L, Obeid KM, Apostolopoulou A, Zhang SX, Permpalung N, Alhatimi H, Silverman MS, Guo H, Rogers BA, MacKenzie E, Pisano J, Gioia F, Rapi L, Prasad GVR, Banegas M, Alonso CD, Doss K, Rakita RM, Fishman JA (2023). Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020. Am J Transplant, 24(4), 653-668. (Read full publication)
    9. Earl A, Greenlee S, Fong K, Imlay H, Spivak ES (2023). Positivity of repeat nasal MRSA PCR screening: a single-center experience. Antimicrob Steward Healthc Epidemiol, 3(1), e226. (Read full publication)
    10. Yamauchi J, Azhar A, Hall IE, Bhalla A, Potluri VS, Tanriover B, Gupta G, Imlay H, Truax C, Balaraman V, Raghavan D, Zimmerman M, Campsen J, Rofaiel G, Baker T, Molnar MZ (2023). Comparison of Short-Term Outcomes in Kidney Transplant Recipients from SARS-CoV-2-Infected versus Noninfected Deceased Donors. Clin J Am Soc Nephrol, 18(11), 1466-1475. (Read full publication)
    11. Wychera C, Imlay HN, Duke ER, Faino A, Li-Huang M, Stevens-Ayers T, Davis C, Lange-Sperandio B, Mallhi KK, Hill JA, Boeckh M, Englund JA, Hingorani S (2022). BK Viremia and Changes in Estimated Glomerular Filtration Rate in Children and Young Adults after Hematopoietic Cell Transplantation. Transplant Cell Ther, 29(3), 187.e1-187.e8. (Read full publication)
    12. Imlay H, Limaye AP (2023). Authors' Reply. Transplantation, 107(3), e83. (Read full publication)
    13. Imlay H, Wagener MM, Vutien P, Perkins J, Singh N, Limaye AP (2022). Increasing Proportion of High-risk Cytomegalovirus Donor-Positive/Recipient-Negative Serostatus in Solid Organ Transplant Recipients. Transplantation. (Read full publication)
    14. Imlay H, Hodowanec AC, Komatsu TE, ORear J, Pikis A, Limaye AP (2022). Reply to Author. Clin Infect Dis, 75, 2047-2048. (Read full publication)
    15. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, ORear J, Pikis A, Randhawa PS, Sawinski D, Singh HK, Westman G, Limaye AP, BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum with the Forum for Collaborative Research (2022). Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Infect Dis, 75, 1210-1216. (Read full publication)
    16. Hannah Imlay and Ajit P Limaye (2022). Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections. UpToDate.
    17. Vutien P, Perkins J, Biggins SW, Reyes J, Imlay H, Limaye AP (2021). Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transpl, 27(9), 1302-1311. (Read full publication)
    18. Imlay HN, Kaul DR (2020). Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis, 73(1), 156-160. (Read full publication)
    19. Imlay H, Dasgupta S, Boeckh M, Stapleton RD, Rubenfeld GD, Chen Y, Limaye AP (2020). Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis, 223(12), 2108-2112. (Read full publication)
    20. Fox ER, Shah M, Vinik R, Brown S, Buckel W, Webb B, Zarndt J, Evans M, Mesdaghi P, Imlay HN, Spivak ES (2021). Developing statewide remdesivir use criteria. Am J Health Syst Pharm, 78(8), 732-735. (Read full publication)
    21. Imlay H, Krantz EM, Stohs EJ, Lan KF, Zier J, Kim HN, Rakita RM, Limaye AP, Wald A, Pergam SA, Liu C (2019). Reported β-Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clin Infect Dis, 71(7), 1587-1594. (Read full publication)
    22. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2020). Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients. Transpl Infect Dis, 22(3), e13255. (Read full publication)
    23. Imlay H, Limaye AP (2020). Current Understanding of Cytomegalovirus Reactivation in Critical Illness. J Infect Dis, 221(Suppl 1), S94-S102. (Read full publication)
    24. Imlay H, Xie H, Leisenring WM, Duke ER, Kimball LE, Huang ML, Pergam SA, Hill JA, Jerome KR, Milano F, Nichols WG, Pang PS, Hirsch HH, Limaye AP, Boeckh M (2019). Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Adv, 4(4), 617-628. (Read full publication)
    25. Ulrich RJ, Bott J, Imlay H, Lopez K, Cinti S, Rao K (2019). Clostridioides difficile Enteritis in Patients Following Total Colectomy-a Rare but Genuine Clinical Entity. Open Forum Infect Dis, 6(11), ofz409. (Read full publication)
    26. Steinbrink J, Imlay H, Rao K, Riddell J 4th (2019). Identifying causes of persistent HIV viremia in adult patients at an academic medical center. SAGE Open Med, 7, 2050312119851006. (Read full publication)
    27. Imlay H, Whitaker K, Fisher CE, Limaye AP (2018). Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis, 20(4), e12928. (Read full publication)
    28. Imlay H, Kaul D, Rao K (2016). Risk factors for Clostridium difficile infection in HIV-infected patients. SAGE Open Med, 4, 2050312116684295. (Read full publication)

    Review

    1. Mendoza MA, Imlay H (2025). Polyomaviruses After Allogeneic Hematopoietic Stem Cell Transplantation. [Review]. Viruses, 17(3). (Read full publication)
    2. Hartlage W, Imlay H, Spivak ES (2024). The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. [Review]. Antimicrob Steward Healthc Epidemiol, 4(1), e214. (Read full publication)
    3. Gorsline CA, Sharma D, Harris CE, Hand J, Imlay H, Stohs EJ, So M, Kumar RN (2024). Not Just an Oxymoron: The Utilitarian's Guide to Antimicrobial Stewardship in Transplant Infectious Diseases. [Review]. Transpl Infect Dis, 26(6), e14399. (Read full publication)
    4. Hand J, Imlay H (2023). Antimicrobial Stewardship in Immunocompromised Patients: Current State and Future Opportunities. [Review]. Infect Dis Clin North Am, 37(4), 823-851. (Read full publication)
    5. Imlay H, Seibert AM, Hanson KE (2023). Pathogen-agnostic immune biomarkers that predict infection after solid organ transplantation. [Review]. Transpl Infect Dis, e14020. (Read full publication)
    6. Imlay H, Spellberg B (2022). Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients. [Review]. Transpl Infect Dis, 24(5), e13896. (Read full publication)
    7. Imlay H, Laundy NC, Forrest GN, Slavin MA (2022). Shorter antibiotic courses in the immunocompromised: the impossible dream? [Review]. Clin Microbiol Infect. (Read full publication)

    Book Chapter

    1. Hannah Imlay and Kimberly E Hanson (). Infection Surveillance Prior to Transplantation. In Amy Leber (Ed.), Clinical Microbiology Procedures Handbook.

    Editorial

    1. Imlay H, Stohs EJ (2025). Collateral Damage: Unpacking Antibiotic Risks in Liver Transplantation. Transpl Infect Dis, e70044. (Read full publication)
    2. Imlay H, Hanson KE (2023). Updates in Prevention, Diagnosis, and Management of Infections Among Solid Organ Transplant Recipients. Infect Dis Clin North Am, 37(3), xiii-xv. (Read full publication)

    Letter

    1. Molnar MZ, Hall IE, Raghavan D, Shihab F, Imlay H, Hanson KE, Gomez CA, Campsen J, Kim R, Baker N, Rofaiel G (2021). Kidney transplantation from SARS-CoV-2-positive deceased donor. [Letter to the editor]. Am J Transplant, 22(4), 1280-1282. (Read full publication)
    2. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2021). Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. [Letter to the editor]. Transpl Infect Dis, 23, e13581. (Read full publication)

    Other

    1. Heeren JR, Imlay HN, Estes RE, Tinsley NA, Steffey KL, Gray ME (2008). Evaluation of foliar-applied insecticides to control pests of alfalfa in Illinois. On Target: 2008 Report (Section 9, pp. 30-2). Department of Crop Sciences, University of Illinois.

  • News & Podcasts

    News